Aug 23, 2023
siRNAgen Therapeutics Announces the Appointment of Renowned Scientific and
siRNAgen Therapeutics, a leading biotech in the RNAi therapeutics space, is pleased to announce the expansion of its advisory board with the inclusion of distinguished scientific and strategic experts.
Aug 4, 2023
siRNAgen Therapeutics Advances SRN-001 to Phase 1a Clinical Trials
Novel siRNA Immunology Drug SRN-001 Breaks New Ground in with Phase 1 Trials in Australia, Leveraging Proprietary SAMiRNA™ Technology for Extrahepatic Delivery
Nov 21, 2022
DeciBio's Q&A with June Park, CEO of siRNAgen Therapeutics
In a recent interview with DeciBio, June Park, CEO of siRNAgen, covered a wide range of topics such as the rapid growth in the siRNA market, expanding RNAi indication areas, and rise of globalization
Sep 29, 2022
siRNAgen Awarded Johnson & Johnson Innovation Seoul Innovation QuickFire Challenge
Johnson & Johnson Innovation LLC and Janssen Korea Ltd. Announce siRNAgen as an Awardee of the Seoul Innovation QuickFire Challenge: Scientific Advancements of Tomorrow in Collaboration with Seoul Metropolitan Government and Korea Health Industry Development Institute
Sep 15, 2022
siRNAgen Therapeutics joins Endless Frontier Labs
siRNAgen Therapeutics has been selected to join the Endless Frontier Labs 2022-2023 cohort. This year’s 75 ground-breaking companies were selected amongst a competitive pool of over 1,000 applicants. siRNAgen will be joining as one of 26 that have been selected for the Life Sciences Track.